-
Use of simply obtained historical, physical, and laboratory data can distinguish gout from other forms of arthritis in many patients and avoid joint aspiration.
-
The FDA has approved the combination of dutasteride (DUT) and tamsulosin (TAM) in a single capsule. Dutasteride is a 5-a reductase inhibitor and tamsulosin is an a-adrenergic antagonist. The combination is marketed by GlaxoSmithKline as Jalyn™.
-
Of late, there has been a renaissance of interest in identification and management of hypogonadism in older men.
-
-
The addition of CACS to a prediction model based upon the traditional risk factors significantly improved the classification of risk and helped to place more individuals in their appropriate risk categories.
-
The ECG shown above was obtained from a 77-year-old woman with chest discomfort and a permanent pacemaker. Do you see any abnormality on this paced tracing?
-
Aggressive approach to CVD reduces MI, folic acid and vitamin B12 for CAD, corticosteroids for acute exacerbations of COPD, prescription drug abuse among young adults, and ARBs and cancer risk.
-
A systematic review of 9 studies showed that the COX-2 inhibitor celecoxib and ibuprofen cause less upper GI bleeding than other NSAIDs. Diclofenac, meloxicam, ketoprofen, indomethacin, and naproxen have intermediate risk. Piroxicam and ketorolac have the highest risk. In general, drugs that have a long half-life or slow-release formulation have the greatest risk of GI bleeding.
-
There is no difference in rates of treatment failure, death, or readmission for COPD between patients treated with oral or intravenous steroids for exacerbation of COPD, but the IV route may be associated with increased cost and length of stay.
-
The first receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor has been approved for the treatment of osteoporosis.
